Introduction
============

Coronary artery disease (CAD) is increasingly prevalent worldwide and is a major cause of cardiovascular mortality. Even if percutaneous coronary intervention (PCI) and effective medical therapies have significantly improved clinical outcomes, certain high risk patients still experienced late cardiovascular events^[@bib1],\ [@bib2])^. Progression of atherosclerosis and late stent failure were the major causes of late cardiovascular events in these CAD patients. A serum marker with prognostic value for late events would help physicians to identify these high-risk patients. Several epidemiologic studies have suggested that elevated homocysteine (HCY) levels are associated with increased risks of atherothrombotic diseases such as CAD, stroke, and peripheral artery disease^[@bib3]--[@bib8])^. Furthermore, Morita H *et al*.^[@bib9])^ and Schnyder G *et al.*^[@bib10])^ reported HCY levels were associated with the late lumen loss after peripheral artery or coronary artery stenting, respectively. However, the prognostic value of HCY levels was not well studied and the conclusions of past studies were inconsistent^[@bib11],\ [@bib12])^. The aim of this study is to clarify the predictive value of plasma HCY levels at index admission for long-term outcomes in patients with coronary artery stenting.

Materials and Methods
=====================

Patient Population and Laboratory Analysis
------------------------------------------

The Cardiovascular Atherosclerosis and Percutaneous TrAnsluminal INterventions (CAPTAIN) registry, a prospective, physician-initiated, single-center database, which includes 6,300 patients undergoing elective or emergent PCI with stenting at Chang Gung Memorial Hospital. We enrolled consecutive patients in the CAPTAIN registry from July 2003 to December 2014, who had acute myocardial infarction or stable CAD with \> 70% stenosis in coronary arteries underwent stent implantations. To minimize the effects of stent property differences between drug eluting stents and bare metal stents (BMS) on long-term clinical outcomes, only patients with BMS implantations were included into analysis. We excluded patients with severe multivessel disease requiring bypass surgery, intolerable for dual antiplatelet therapy, or not follow the study protocol. Patients with renal insufficiency (serum creatinine level \> 1.5 mg/dL) or concurrent active infections, inflammatory disorders, or cancer were also excluded to minimize the influence of comorbidities on HCY levels. Stent implantation was performed through the femoral or radial artery according to standard techniques. The type of stent was based on the indication and available stent size. After initial stent deployment, high-pressure balloon inflation (≥ 14 atm) was applied in most patients. The creatine kinase myocardial-band (CKMB) isoenzyme and troponin I were measured in all of the patients immediately and 6 h after the procedure to detect periprocedure myocardial infarction (MI). All of the patients received standard ischemia heart disease therapies after procedure, including dual antiplatelet therapy with aspirin and clopidogrel or ticagrelor, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Blood samples for plasma total HCY were collected after overnight fasting before index coronary angiography and intervention. The plasma total HCY level was measured by high-performance liquid chromatography with fluorescence detection (Hitachi Labospect 008, AS, Japan). We use a cutoff value of 12 µmol/L for hyperhomocysteinemia^[@bib10])^. The study protocol was approved by the Institutional Review Board of Chang Gung Medical Foundation. All participants provided informed consents to undergo the procedure and follow-up protocol.

Angiographic Evaluation
-----------------------

The minimal luminal diameter (MLD), reference vessel diameter (RVD), percent of diameter stenosis (DS%), and balloon diameter were measured from multiple projections using the automatic edge-detection method. Acute gain was defined as the difference in MLD between before and after stenting. The quantitative coronary angiographic analysis was performed by two experienced interventional cardiologists, and images were selected with a end-diastolic cine-frame of the most severe and nonforeshortened projection. A contrast-filled guiding catheter was used as a reference for calibration. The interobserver correlation coefficient (r) was 0.93 (*p* \< 0.01), and the intraobserver correlation coefficient was 0.95 (*p* \< 0.01).

Definitions of the Endpoints
----------------------------

The study endpoint was the occurrence of major adverse cardiac events (MACE), a composite of cardiac death, nonfatal MI, stroke, target lesion revascularization, new lesion stenting, and necessitation of coronary bypass surgery. Cardiac death was defined as any death due to immediate cardiac cause, such as MI, low-output pumping failure, or fatal arrhythmia. The MI was diagnosed if the patient experienced prolonged chest pain, ischemic ST-T changes shown on electrocardiography, and elevated CK-MB isoenzyme or troponin I levels. Clinical follow-up visits at the outpatient clinics were scheduled at 1, 2, 3, 6, 9, and 12 months, and every 3 months thereafter. Information regarding clinical events was obtained from hospital medical records, the referring physician, and phone interviews with the patients or their relatives through December 30, 2015.

Statistical Analysis
--------------------

Data were prospectively collected and analyzed using SPSS statistical software package (version 22.0, IBM) for all statistical analyses. Continuous variables were represented as means ± standard deviation (SD) and compared between groups using a two-tailed *t* test. Categorical variables were presented as numbers (percentages) and compared with a Fisher\'s exact test. Cox proportional hazard regression models were used to determine the relationship between plasma HCY levels and MACE rates. They were presented as hazard ratios (HRs) with 95% confidence intervals (CIs) and adjusted for confounding factors including variants in clinical and angiographic characteristics. MACE-free survival curve was depicted by the Kaplan--Meier method and differences between the two groups were assessed by the log-rank test. A *p* value less than 0.05 was considered statistically significant.

Results
=======

Baseline Characteristics
------------------------

A total of 1,340 patients were in accordance with eligibility criteria for study participants in the CAPTAIN registry. There were 33 patients excluded from relevant analyses for missing data. Finally, 1,307 patients (mean age 62 ± 12 years, range 24 -- 93 years; 81.5% male) with 1,604 lesions and 1,800 BMS implantations were consecutively enrolled for analyses (**[Fig. 1](#F1){ref-type="fig"}**). The patients were divided into two groups according to baseline plasma total HCY level with a cutoff value of 12 µmol/L: group I (883 patients, HCY \< 12 µmol/L), group II (424 patients, ≥ 12 µmol/L). Comparisons of the baseline characteristics are shown in **[Table 1](#T1){ref-type="table"}**. The patients in group II were significantly older (65.2 ± 12 vs. 61.1 ± 12 years, *p* \< 0.001), and there were more patients with diabetes (36.1% vs. 27.9%, *p* = 0.003), hypertension (63.7% vs. 56.3%, *p* = 0.033), history of stroke (7.8% vs. 4.8%, *p* = 0.031), and left ventricular systolic dysfunction (ejection fraction \< 40%) at the initial event (17.9% vs. 9.3%, *p* \< 0.001). The mean plasma total HCY levels in group I and II were 8.7 µmol/L and 16.4 µmol/L, respectively (**[Table 1](#T1){ref-type="table"}**). The mean serum creatinine level in group II was higher than that in group I (1.12 ± 0.24 vs. 1.01 ± 0.24 mg/dL, *p* \< 0.001) and the mean estimated glomerular filtration rates (eGFR), calculated by the Modification of Diet in Renal Disease (MDRD) equation, in group I and II were 74.9 ± 26.8 and 65.8 ± 20.1 mL/min/1.73 m^2^, respectively (*p* \< 0.001).

![Flow diagram of patient enrollment and analysis\
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###### Baseline clinical characteristics (*n* = 1,307)

  Homocysteine level                   \< 12.0 µmol/L   ≥ 12.0 µmol/L   *P* value
  ------------------------------------ ---------------- --------------- -----------
  Age ± SD (years)                     61.1 ± 12        65.2 ± 12       \< 0.001
  Woman, n (%)                         169 (19.1)       73 (17.2)       0.447
  Diabetes mellitus, n (%)             246 (27.9)       153 (36.1)      0.003
  Hypertension, n (%)                  497 (56.3)       270 (63.7)      0.033
  Currently smoking, n (%)             397 (45.0)       170 (40.1)      0.107
  Hyperlipidemia, n (%)                462 (51.6)       203 (46.1)      0.063
  Hx of PCI, n (%)                     99 (11.2)        60 (14.2)       0.148
  Hx of stroke, n (%)                  42 (4.8)         33 (7.8)        0.031
  Hx of MI, n (%)                      468 (53.0)       231 (54.5)      0.636
  Homocysteine, mean ± SD, µmol/l      8.7 ± 2.0        16.4 ± 8.5      \< 0.001
  Serum creatinine, mean ± SD, mg/dL   1.01 ± 0.23      1.12 ± 0.24     \< 0.001
  eGFR, mean ± SD, ml/min/1.73 m^2^    74.9 ± 26.8      65.8 ± 20.1     \< 0.001
  Stable angina, n (%)                 486 (55.0)       242 (57.1)      0.488
  ACS, n (%)                           397 (45.0)       182 (42.9)      0.521
  LVEF \< 40%, n (%)                   76 (9.3)         70 (17.9)       \< 0.001
  Cardiogenic shock, n (%)             46 (5.2)         27 (6.4)        0.440
  Multivessel disease, n (%)           578 (65.5)       295 (69.6)      0.149

ACS: acute coronary syndrome; eGFR: estimated glomerular filtration rate, calculated by the Modification of Diet in Renal Disease (MDRD) equation. Hx: history of occurrence 6 months or longer before the study; LVEF: left ventricular ejection fraction, measured by angiography; MI: myocardial infarction; PCI: percutaneous coronary intervention; SD: standard deviation.

Angiographic Characteristics
----------------------------

There were total 1,082 lesions in group I and 522 lesions in group II, of which 1,253 (78.1%) were complex lesions (type B2 and C), 107 (6.7%) were bifurcation lesions, and 117 (7.3%) were ostial lesions. The mean lesion length was 20 ± 10 mm. There was no significant difference in lesion location, length, or complexity between the two groups. However, patients in groups II had more calcified lesions (17.0% vs. 11.6%, *p* = 0.004) and fewer thrombus-containing lesions (11.1% vs. 15.1%, *p* = 0.037). For PCI-related characteristics, there was no significant difference in the pre- or post-procedure DS%, MLD, or RVD of the target lesions. Also, there was no significant difference in the sizes and lengths of the implanted coronary artery stents between the two groups (**[Table 2](#T2){ref-type="table"}**). A total of 1,800 stents were implanted including 40 Bx Velocity (Johnson and Johnson, Miami Lakes, Florida, USA), 427 Driver (Medtronic, Santa Rosa, CA, USA), 122 Express (Boston Scientific, Natick, Massachusetts, USA), 45 Integrity (Medtronic), 88 Liberte (Boston Scientific), 14 Multilink (Guidant, Santa Clara, CA, USA), 1 Multi-Link TETRA (Guidant), 312 Multi-Link PENTA (Guidant), 76 Multi-Link PIXEL (Guidant), 469 Multi-Link VISION (Abbott Vascular, Santa Clara, CA, USA), 53 Multi-Link ZETA (Abbott), 27 Omega (Boston Scientific), 61 R (Orbus-Neich, Hong Kong), and 65 S7 (Medtronic) stents.

###### Angiographic and PCI-related characteristics (*n* = 1,604)

  Homocysteine level                                                     \< 12.0 µmol/L   ≥ 12.0 µmol/L   *P* value
  ---------------------------------------------------------------------- ---------------- --------------- -----------
  Complex lesion (type B2 or C[\*](#tfn1){ref-type="table-fn"}), n (%)   832 (76.9)       421 (80.7)      0.094
  Target vessel site                                                                                      0.924
  Left main, n (%)                                                       24 (2.2)         14 (2.7)        
  LAD, n (%)                                                             442 (40.9)       221 (42.3)      
  LCx, n (%)                                                             207 (19.1)       94 (18.0)       
  RCA, n (%)                                                             402 (37.2)       189 (36.2)      
  Graft, n (%)                                                           7 (0.6)          4 (0.8)         
  Ostial lesion, n (%)                                                   78 (7.2)         39 (7.5)        0.838
  Bifurcation, n (%)                                                     76 (7.0)         31 (5.9)        0.456
  Lesion length, mean ± SD (mm)                                          20.2 ± 10        20.5 ± 11       0.629
  Stent size, mean ± SD (mm)                                             3.3 ± 0.7        3.3 ± 0.6       0.470
  Calcified, n (%)                                                       126 (11.6)       89 (17.0)       0.004
  Thrombus containing, n (%)                                             163 (15.1)       58 (11.1)       0.037
  Number of stents per lesion                                            1.10             1.12            0.178
  Pre-procedure target lesion                                                                             
      % diameter stenosis, mean ± SD                                     82.5 ± 13        82.9 ± 13       0.547
      MLD (mm), mean ± SD                                                0.58 ± 0.5       0.57 ± 0.5      0.627
      RVD (mm), mean ± SD                                                3.32 ± 0.6       3.33 ± 0.6      0.884
  Post-procedure target lesion                                                                            
      % diameter stenosis, mean ± SD                                     6.4 ± 6          6.6 ± 6         0.523
      MLD (mm), mean ± SD                                                3.36 ± 0.5       3.10 ± 0.5      0.479
      RVD (mm), mean ± SD                                                3.32 ± 0.6       3.36 ± 0.6      0.894
  Acute gain (mm), mean ± SD                                             2.52 ± 0.6       2.53 ± 0.6      0.812

LAD: left anterior descending artery; LCx: left circumflex artery; LIMA: left internal mammary artery; OM: obtuse margin; MLD: minimal luminal diameter; PCI percutaneous coronary intervention; PDA: posterior descending artery; PL: posterolateral artery; RCA: right coronary artery; RVD: reference vessel diameter; SD: standard deviation.

A complex lesion was defined as a lesion of type B2 and C according to the classification of the American College of Cardiology and the American Heart Association.

In-Hospital Cardiac Events
--------------------------

The in-hospital cardiac events in the two groups are shown in **[Table 3](#T3){ref-type="table"}**. The overall and cardiac-related mortality rates were higher in group II than in group I (2.9% vs. 0.7%, *p* = 0.004; 2.4% vs. 0.7%, *p* = 0.014, respectively). However, there were no significant differences in the incidence of MI, acute, and subacute stent thrombosis, emergency bypass surgery, nonfatal stroke, or in-hospital MACE between the two groups.

###### In-hospital cardiac events

  Homocysteine level                 \< 12.0 µmol/L   ≥ 12.0 µmol/L   *P* value
  ---------------------------------- ---------------- --------------- -----------
  Number of patients                 883              424             
  Death, n (%)                       6 (0.7)          12 (2.9)        0.004
      Cardiac                        6 (0.7)          10 (2.4)        0.014
      Non-Cardiac                    0 (0)            2 (0.5)         0.105
  Non-fatal MI, n (%)                                                 0.607
      NSTEMI                         18 (2.0)         8 (1.9)         1.00
      STEMI                          2 (0.2)          0               1.00
  Acute stent thrombosis, n (%)      3 (0.3)          2 (0.5)         0.662
  Subacute stent thrombosis, n (%)   5 (0.6)          4 (0.9)         0.483
  Emergent bypass surgery, n (%)     2 (0.2)          1 (0.2)         1.000
  Non-fatal stroke, n (%)            2 (0.2)          0               1.00
  MACE, n (%)                        33 (3.7)         19 (4.5)        0.546

MACE: major adverse cardiac event; MI: myocardial infarction; NSTEMI: non ST-segment elevation myocardial infarction; STEMI: ST- segment elevation myocardial infarction

Long-Term Clinical Outcomes
---------------------------

A total of 1,289 patients, who survived and discharged from hospital after PCI, were followed up for a mean of 58 ± 41 months. The patients in group II had a significantly higher mortality rate than those in group I (12.1% vs. 6.4%, *p* = 0.001) and majority were from cardiac death (8.0% vs. 3.4%, *p* = 0.001). In addition, the patients in group II had a higher percentage of new coronary artery lesions requiring stenting than patients in group I (13.6% vs. 9.5%, *p* = 0.034). Overall, the group II patients had a higher MACE rate than group I patients (33.3% vs. 25.6%, *p* = 0.005) (**[Table 4](#T4){ref-type="table"}**). In Kaplan--Meier analysis, there was a significant difference in the MACE-free survival rate between the two groups (log-rank test; *p* = 0.001) (**[Fig. 2](#F2){ref-type="fig"}**). The univariate Cox proportional hazards analysis showed that the MACE rates were significantly associated with diabetes mellitus, LVEF \< 40%, multivessel disease, complex type B2 or C lesion, postprocedure MLD, serum creatinine level, and plasma HCY level ≥ 12 µmol/L. After adjusting for factors of age, gender, hypertension, diabetes mellitus, hyperlipidemia, serum creatinine, HCY level \> 12 µmol/L, multivessel disease, type B2 or C lesions, post-procedure MLD, and LVEF \< 40% in multivariable analysis, elevated plasma HCY levels (≥ 12 µmol/L) remained a statistically significant predictor for long-term cardiovascular outcomes, with a HR of 1.29 (95% CI: 1.02--1.64, *p* = 0.036). Other significant predictors were LVEF \< 40% (HR: 1.52, 95% CI: 1.11 -- 2.09, *p* = 0.010), multivessel disease (HR: 1.51, 95% CI: 1.17-- 1.95, *p* = 0.002), post-procedure MLD (HR: 0.66, 95% CI: 0.53 --- 0.83, *p* \< 0.001), and serum creatinine (HR: 1.69, 95% CI: 1.06 --- 2.71, *p* = 0.027) (**[Table 5](#T5){ref-type="table"}**). Moreover, the plasma HCY values were divided into quintiles to examine their relationship with the long-term MACEs (**[Table 6](#T6){ref-type="table"}**). There was a graded association between HCY levels and MACE rates, which compared with quintiles 1--3, the adjusted HRs in quintile 4 (HCY range 11.3--13.4 µmol/L) and quintile 5 (HCY range \> 13.4 µmol/L) were 1.06 (95% CI: 0.78--1.44) and 1.37 (95% CI: 1.03--1.82), respectively.

###### Clinical events during long-term follow-up (*n* = 1,289, 58 ± 41 months)

  Homocysteine level                       \< 12.0 µmol/L   ≥ 12.0 µmol/L   *P* value
  ---------------------------------------- ---------------- --------------- -----------
  Number of patients                       876              413             
  Overall mortality, n (%)                 56 (6.4)         50 (12.1)       0.001
      Cardiac, n (%)                       30 (3.4)         33 (8.0)        0.001
      Non-cardiac, n (%)                   26 (3.0)         17 (4.1)        0.318
  Non-fatal MI, n (%)                      31 (3.5)         18 (3.8)        0.450
  Target lesion revascularization, n (%)   87 (9.9)         46 (11.2)       0.494
  New lesion stenting, n (%)               83 (9.5)         56 (13.6)       0.034
  Coronary bypass surgery, n (%)           15 (1.7)         9 (2.2)         0.659
  Non-fatal stroke, n (%)                  19 (2.2)         9 (2.2)         1.00
  MACE, n (%)                              224 (25.6)       137 (33.3)      0.005

MACE: major adverse cardiac events; MI: myocardial infarction

![The MACEs-free survival by Kaplan--Meier analysis between groups\
The event-free survival rate was significantly higher in the group I patients with lower homocysteine levels at admission (\< 12 µmol/L) (Log-rank test, *p* = 0.001).\
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###### Predictors of long-term major cardiac events

  Cox Proportional Hazards Regression   Univariate   Multivariate                                 
  ------------------------------------- ------------ -------------- ---------- ------ ----------- ----------
  Predictors                            HR           95% CI         P value    HR     95%CI       P value
  Age (every 10 years)                  1.08         0.99∼1.17      0.090      1.00   0.99∼1.01   0.658
  Female                                0.99         0.76∼1.30      0.974      1.09   0.79∼1.50   0.598
  Diabetes mellitus                     1.39         1.12∼1.72      0.003      1.24   0.97∼1.59   0.085
  Hypertension                          1.15         0.93∼1.42      0.427      1.01   0.80∼1.27   0.954
  Hyperlipidemia                        1.08         0.88∼1.33      0.463      1.07   0.84∼1.35   0.594
  ACS                                   1.07         0.87∼1.32      0.515                         
  LVEF \< 40%                           1.54         1.15∼2.07      0.004      1.52   1.11∼2.09   0.010
  Cardiogenic shock                     0.97         0.59∼1.59      0.892                         
  Multi-vessel disease                  1.63         1.29∼2.06      \< 0.001   1.51   1.17∼1.95   0.002
  Type B2 or C lesions                  1.50         1.09∼2.05      0.012      1.34   0.95∼1.89   0.092
  Post-procedural MLD (mm)              0.64         0.52∼0.79      \< 0.001   0.66   0.53∼0.83   \< 0.001
  Creatinine (mg/dL)                    1.94         1.23∼3.05      0.004      1.69   1.06∼2.71   0.027
  eGFR (ml/min/1.73 m^2^)               0.99         0.99∼1.01      0.109      1.01   1.00∼1.12   0.065
  HCY (≥ 12 µmol/L)                     1.43         1.15∼1.77      0.001      1.29   1.02∼1.64   0.036

ACS: acute coronary syndrome; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; MLD: minimal luminal diameter; HCY: plasma total homocysteine level.

###### Long-term outcomes by homocysteine quintiles

                  Patient number   HCY range    Event number   Event rate   [\*](#tfn2){ref-type="table-fn"} Adjusted HR   95% CI       *P* value
  --------------- ---------------- ------------ -------------- ------------ ---------------------------------------------- ------------ -----------
  Quintile 1--3   789              \< 11.3      201            25.4         1                                              --           --
  Quintile 4      293              11.3--13.4   84             28.7         1.06                                           0.78\~1.44   0.697
  Quintile 5      206              \> 13.4      75             36.4         1.37                                           1.03\~1.82   0.032

Adjusted HR: hazard ratio adjusted for age, sex, hypertension, diabetes mellitus, hyperlipidemia, serum creatinine, multi-vessel disease, post procedure MLD, and LVEF \< 40%

HCY: plasma total homocysteine level. LVEF: left ventricular ejection fraction; MLD: minimal luminal diameter.

Discussion
==========

In our retrospective analysis of a single center registry, 1,307 patients with coronary artery diseases after bare metal stent implantation were included for nearly 5 years follow-up. The patients with hyperhomocysteinemia (≥ 12 µmol/L) had a higher long-term MACE rate, mainly from cardiac mortality and new lesion stenting. After adjusting for multiple clinical, angiographic, and PCI-related variables, the association remained significant (HR, 1.29; 95% CI: 1.02--1.64). There is a dose dependent association between HCY levels and risks for long-term MACE, where the adjusted HRs in quintile 4 (HCY range 11.3--13.4 µmol/L) and quintile 5 (HCY range \> 13.4 µmol/L) were 1.06 (95% CI: 0.78--1.44) and 1.37 (95% CI: 1.03--1.82), respectively.

Since McCully *et al.*^[@bib13])^ described vascular diseases in patients with severe hyperhomocysteinemia (\> 100 µmol/L) in 1969, subsequent case control and epidemiologic studies have shown a strong association between plasma HCY levels and the risks of atherosclerotic diseases. As observational studies have shown, even mildly elevated plasma HCY levels (between 11.4 and 14.3 µmol/L) increase the risk of cardiovascular events^[@bib14],\ [@bib15])^. However, the pathophysiological mechanisms were not fully understood. As implied from basic research on the mechanism of HCY associated with vascular injury^[@bib16]--[@bib19])^, HCY produced reactive oxygen species and caused lipid peroxidation, platelets and leukocytes activation, and increased prothrombotic factors, which resulted in vascular inflammation, thrombus formation. Furthermore, HCY causes endothelial dysfunction with impaired release of nitric oxide and vasodilatation in response to shear stress in vascular wall, which predisposes to vulnerable plagues rupture, contributes to atheroma progression, and ultimately gives rise to vascular events. Case control studies showed HCY level was significantly higher in patients with acute coronary syndrome (ACS)^[@bib20],\ [@bib21])^. In regard to the role of HCY in PCI, researchers also reported that patients with coronary slow flow phenomenon had higher HCY levels^[@bib22])^, increased oxidative stress markers and impaired endothelial cell function^[@bib23])^. Although hyperhomocysteinemia was considered to be associated with more ACS and periprocedural acute thrombotic events in previous reports, there was no significant difference in incidence of initial ACS presentation and in-hospital acute events between two groups in our study. We thought it could be explained by two main reasons. Frist, insufficient numbers of in-hospital thrombotic events and relatively mild to moderate elevated HCY levels in both groups are not enough to detect the difference in the prespecified clinical outcomes. Second, the thrombotic events in CAD caused from a complex interaction between numerous factors from patient-related, pharmacologic-related, procedural-related, or device-related related factors that might be unequal distribution between two groups in a nonrandomized trial.

With respect of the issue of increased cardiac mortality in patients with hyperhomcysteinemia, some relevant clinical observation results might explain this background issue. First, HCY levels correlated to the severity and extent of coronary atherosclerosis^[@bib24])^ and associated with vascular calcification^[@bib25],\ [@bib26])^ and unstable atherosclerotic plagues^[@bib27])^. These anatomic factors increased the difficulties of coronary intervention and associated with acute complications and worse long-term clinical outcomes. Second, the prothrombotic and proinflammatory effects of HCY are associated with coronary slow flow during intervention and may impair angiogenesis and collateral vessels development^[@bib28])^, resulting in inadequate myocardial reperfusion, increased extent of myocardial necrosis, and finally ventricular pumping failure and worse long-term outcomes. However, we did not prospectively include the prespecified variables, such as vulnerability of atherosclerotic plagues or quantification of coronary slow flow during PCI in our initial study protocol and thus, there was no complete clinical data to analysis this association. Nevertheless, this issue is sufficiently noteworthy to merit additional well-designed studies.

In human studies, Kosokabe *et al.*^[@bib29])^ observed a positive correlation between plasma HCY levels and atherosclerotic plaque areas in reference segments of coronary arteries, which were measured by intravascular ultrasound 6 months after the intervention. This evidence supports the atherogenic propensity of HCY and also could explain our study results, which more numbers of new lesions stenting and worse long-term outcomes in our patients with hyperhomocystinemia.

However, the results in past studies were inconsistent. In the late 1990s, Nygard *et al.*^[@bib30])^ reported a strong and graded relationship between plasma HCY levels and the overall mortality in 587 patients with angiographically confirmed CAD after a median follow-up of 4.6 years. In their study, patients with a homocysteine level \> 15 mmol/L had a 24.7% total mortality rate, compared with 3.8% for those with a homocysteine level \< 9 mmol/L (*p* = 0.02). Later, Stubbs *et al.*^[@bib31])^ also stated the similar association of plasma HCY levels and the long-term prognosis (median 2.5 years) in 440 patients with acute coronary syndrome, in which patients with a HCY level (\> 12.2 µmol/L) had a 2.6-fold higher risk of cardiac death and myocardial re-infarction. In contrast, a prospective observational study by Zairis *et al.*^[@bib12])^, including 483 patients with either stable angina or acute coronary syndrome after successful coronary stenting, found no significant association between plasma HCY levels and the composite endpoint of cardiac death, MI, or re-hospitalization for angina after a median follow-up of 22 months. The disparate results may be attributed to the shorter follow-up duration and different enrolled patient population and study endpoints in later study. In Zairis *et al.* study, patients with CAD and LVEF \< 35%, implicating severe and extensive disease may have a higher plasma HCY level and poor prognosis^[@bib4])^, were excluded. Patients with ST segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI) presented more than 6 h or 24 h of index pain, respectively, were excluded. The endpoint of rehospitalization for angina may not be objectively and difficult to differentiate in some clinical situation. These enrolled criteria and study endpoints were also different from our study.

Even though evidence has shown an association between elevated plasma HCY levels and increased risks of late cardiac events and poor prognosis in patients with CAD, in randomized controlled trials, secondary prevention management with folic acid and vitamins failed to prevent or decrease cardiovascular events, even decreasing homocysteine levels^[@bib32]--[@bib34])^. However, it seems too early to make a conclusion before further well-designed clinical trials with different dosages or agents were performed. A longer follow-up period and specific patient population with moderately elevated homocysteine levels may be necessary to observe impacts of HCY on progression of coronary atherosclerosis and cause late stent failure and clinical events. In fact, a recent meta-analysis on patients with chronic kidney disease found significant benefits of reducing risks of cardiovascular disease from folate treatment, especially in those with a higher baseline homocysteine level (mean \> 25 µmol/L, relative risk 0.87, *p* = 0.049)^[@bib35])^. The further research to investigate the pathogenesis of HCY in atherosclerotic disease is important to contribute a newly potential therapeutic target to reduce homocysteine levels and improve outcomes.

Limitations
===========

There were several limitations in this study. First, we used a cutoff value of HCY levels 12 µmol/L make uneventful distribution of the study population. Second, the optimal timing for blood collection and testing methods for plasma HCY levels have not been well defined. We sample blood in early morning after fasting for more than 12 h and within 24 h after admission. HCY levels may influence by numerous environmental factors such as dietary contents, which we could not estimate and adjust. Third, the methylene tetrahydrofolate reductase (MTHFR) enzyme, folic acid, vitamin B6, and vitamin B12 are required for metabolizing homocysteine to methionine or cysteine. Gene polymorphism of MTHFR C677T and dietary deficiency of folic acid, vitamin B6, or vitamin B12 are associated with hyperhomocysteinemia. In our study protocol, we did not routinely measure serum folate, vitamin B12, and gene polymorphism. Thus, we could not analyze the interaction between folic acid, vitamin B12, gene polymorphism, and risks of cardiovascular events. However, the association of MTHFR genotype and cardiovascular events is still controversial, and it could be modified by the folate status, where high folate levels reduced the effect of MTHFR C677T on HCY levels^[@bib7],\ [@bib36])^. Thus, we suggested that HCY levels reflect the influence of the gene--environment interactions and should be a more relevant factor to predict cardiovascular outcomes. Fourth, this is a single center prospective study and the results may not be applicable to other racial and ethnic groups.

Conclusions
===========

An elevated HCY level (≥ 12 µmol/L) increased the risk of long-term cardiovascular events in patients who undergo intracoronary BMS implantations. After adjusting for clinical, angiographic, and PCI-related variables, an elevated homocysteine level remained a robust independent predictor for long-term clinical outcomes. Even randomized trials failed to demonstrate clinical benefits of HCY reducing therapies, HCY levels remain a useful clinical predictive marker for early identification of high-risk patients with worse long-term outcomes after coronary artery stenting.
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